By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cyclacel Pharmaceuticals, Inc. 

200 Connell Drive
Suite 1500
Berkeley Heights  New Jersey  07922  U.S.A.
Phone: 908-517-7330 Fax: 866-271-3466


Company News
Cyclacel Pharmaceuticals, Inc. (CYCC) Announces Receipt Of Nasdaq Staff Determination; Company To Request Hearing 2/8/2016 7:34:20 AM
Cyclacel Pharmaceuticals, Inc. (CYCC) To Present At The 18th Annual BIO CEO & Investor Conference 2/2/2016 8:05:51 AM
Cyclacel Pharmaceuticals, Inc. (CYCC) Reviews 2015 Achievements And Announces Key Business Objectives For 2016 1/11/2016 8:24:26 AM
Molecular Basis For Development Of Cyclacel Pharmaceuticals, Inc. (CYCC)’s CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium 12/14/2015 7:41:02 AM
CYC065, Cyclacel Pharmaceuticals, Inc. (CYCC)’s Novel CDK2/9 Inhibitor, Prolongs Survival In MYCN-Addicted Neuroblastoma Models 11/23/2015 7:21:02 AM
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Third Quarter 2015 Financial Results 11/13/2015 8:29:56 AM
Mechanistic Rationale For CYC065, Cyclacel Pharmaceuticals, Inc. (CYCC)l’s CDK2/9 Inhibitor, In Targeted Solid Tumors And Hematological Malignancies Presented At AACR-AACR-EORTC International Conference 11/9/2015 10:24:16 AM
Cyclacel Pharmaceuticals, Inc. (CYCC) To Release Third Quarter 2015 Financial Results 11/5/2015 10:26:53 AM
Data To Be Presented On CYC065, Cyclacel Pharmaceuticals, Inc. (CYCC)’s CDK2/9 Inhibitor, At AACR-National Cancer Institute-EORTC International Conference 10/27/2015 7:54:38 AM
Cyclacel Pharmaceuticals, Inc. (CYCC) Doses First Patient In Phase I Trial Of Its Novel CDK2/9 Inhibitor, CYC065, For The Treatment Of Advanced Solid Tumors 10/22/2015 7:29:12 AM